Search results
Results from the WOW.Com Content Network
An abnormal basal metabolic rate is not necessarily indicative of disease; a number of physiological factors can alter the BMR by influencing cellular metabolic activity. [1] For instance, males are more likely than females to have a high BMR, and in women, the BMR may rise to abnormal levels during pregnancy or lactation. [2]
There was an average BSA of 1.73 m 2 for 3,000 cancer patients from 1990 to 1998 in a European Organisation for Research and Treatment of Cancer (EORTC) database. [19] During 2005 there was an average BSA of 1.79 m 2 for 3,613 adult cancer patients in the UK. Among them the average BSA for men was 1.91 m 2 and for women was 1.71 m 2. [20]
The basal metabolic rate accounts for about 70% of the daily calorie expenditure by individuals. It is influenced by several factors. In humans, BMR typically declines by 1–2% per decade after age 20, mostly due to loss of fat-free mass, [3] although the variability between individuals is high. [4]
In some cases, using BMI can result in "muscular athletes" being labeled as obese, he noted, and people with "normal" BMI can sometimes have "harmful" levels of visceral (abdominal) fat.
In Canada, the most common skin cancer is basal-cell carcinoma (as much as one-third of all cancer diagnoses), affecting 1 in 7 individuals over a lifetime. [66] This tumor accounts for approximately 70% of non-melanoma skin cancers. In 80 percent of all cases, basal-cell carcinoma affects the head or neck skin. [65]
An advantage is the cosmetic result: after treatment, the skin resembles normal skin without the usual scarring and morbidity associated with standard excision. Imiquimod is not FDA-approved for any squamous-cell carcinoma. In general, squamous-cell carcinomas have a high risk of local recurrence, and up to 50% do recur. [60]
Skin cancer is the most common form of cancer, globally accounting for at least 40% of cancer cases. [5] [20] The most common type is nonmelanoma skin cancer, which occurs in at least 2–3 million people per year. [6] [21] This is a rough estimate; good statistics are not kept. [1]
A study examining over 4,000 biopsied skin lesions identified clinically as seborrheic keratoses showed 3.1% were malignancies. Two-thirds of those were squamous cell carcinoma. [11] To date, the gold standard in the diagnosis of seborrheic keratosis is represented by the histolopathologic analysis of a skin biopsy. [12]